Teladoc Health (NYSE:TDOC) Rating Increased to Buy at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health (NYSE:TDOC) from a hold rating to a buy rating in a research report released on Tuesday, MarketBeat Ratings reports. They currently have $11.00 target price on the health services provider’s stock.

TDOC has been the subject of several other research reports. BMO Capital Markets dropped their target price on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a report on Thursday, February 26th. Piper Sandler restated an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Barclays began coverage on Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Stifel Nicolaus cut their price objective on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. Finally, Leerink Partners decreased their target price on Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research note on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus price target of $7.76.

Teladoc Health Trading Up 5.5%

Shares of TDOC stock opened at $5.59 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.77 and a quick ratio of 2.67. The firm has a market cap of $997.26 million, a PE ratio of -4.90 and a beta of 2.13. The company has a 50-day moving average of $5.72 and a two-hundred day moving average of $7.09. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.77.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The business had revenue of $642.27 million for the quarter, compared to the consensus estimate of $635.33 million. During the same period in the previous year, the firm earned ($0.28) EPS. The business’s revenue was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, analysts predict that Teladoc Health will post -1.16 EPS for the current year.

Insiders Place Their Bets

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at $1,533,904.68. This trade represents a 7.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.58% of the stock is currently owned by insiders.

Institutional Trading of Teladoc Health

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Teladoc Health by 4.2% in the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after acquiring an additional 891,732 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Teladoc Health by 8.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after purchasing an additional 605,061 shares in the last quarter. Geode Capital Management LLC grew its stake in Teladoc Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock worth $29,324,000 after purchasing an additional 18,394 shares in the last quarter. Jupiter Asset Management Ltd. increased its holdings in Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after purchasing an additional 2,880,008 shares during the period. Finally, Nuveen LLC increased its holdings in Teladoc Health by 38.7% during the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock worth $18,618,000 after purchasing an additional 742,240 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Deutsche Bank upgraded TDOC from Hold to Buy and set an $11 price target (roughly ~97% above the recent price), explicitly citing valuation as the reason for the upgrade. This is the main catalyst for renewed buying interest. Teladoc jumps as Deutsche Bank upgrades
• Positive Sentiment: Analysts pointed to a “compelling” valuation after TDOC’s Talkspace-related transaction/partnership as supporting upside, which helped spark a ~10% pre-market pop in some headlines. That narrative (value + deal optionality) is driving short-term buying. TDOC stock surges 10% pre-market, analyst cites ‘compelling’ valuation after Talkspace deal
• Positive Sentiment: Market write-ups and analyst notes (Benzinga, 247WallSt) are echoing the same view—strategic partnerships and business pivots are reshaping TDOC’s risk/reward and prompting fresh buy-side interest. Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
• Neutral Sentiment: Management presented at the Barclays 28th Annual Global Healthcare Conference (transcript available). Presentations can provide greater visibility on strategy and cost plans but don’t always change near-term fundamentals unless guidance or new deals are announced. Teladoc Health, Inc. (TDOC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.